APAndre Sampaio Pupo

Andre Sampaio Pupo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andre Sampaio Pupo has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • François Noël

    Universidade Federal do Rio de Janeiro, Brasil

    2 shared publications
  • Juliana Akinaga

    Department of Pharmacology Instituto de Biociências, UNESP Botucatu Brazil

    2 shared publications
  • A.J.S. Niederauer

    Universidade Estadual de Campinas

    1 shared publication
  • Amanda Reis Pimenta

    Laboratory of Biochemical and Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (B.M.C.S.Q., A.R.P., A.C.S.d.S., C.L.M.S., F.N.); Department of Pharmacology, Instituto de Biociências, UNESP, Botucatu, Brazil (A.S.P.); and Health Sciences Faculty, Universidade de Brasília, Brasília, Brazil (L.A.S.R.).

    1 shared publication
  • Andre Willian Hollais

    Department of Physiology, Universidade Federal de São Paulo, R. Botucatu, 862, 04023062 São Paulo, SP, Brazil

    1 shared publication
  • Anne Caroline Santos da Silva

    Laboratory of Biochemical and Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (B.M.C.S.Q., A.R.P., A.C.S.d.S., C.L.M.S., F.N.); Department of Pharmacology, Instituto de Biociências, UNESP, Botucatu, Brazil (A.S.P.); and Health Sciences Faculty, Universidade de Brasília, Brasília, Brazil (L.A.S.R.).

    1 shared publication

Latest Publications

  • Open Access

    Alpha1-adrenoceptor antagonists block the positive chronotropic effect of 6-nitrodopamine in the isolated rat right atrium

    by B.L. Alves, A.J.S. Niederauer, J. Britto-Júnior, J.F. Sobanski, T.C.C. de Assis, D.L. Oliveira, G. Said, G.D. Mendes, A.S. Pupo, S. Marcondes, et al.

    6-Nitrodopamine (6-ND) released from isolated rat atria produces potent positive chronotropic actions. Direct negative chronotropic responses to some selective α1-adrenoceptor (AR) antagonists like prazosin have been reported. Since α1-AR antagonists inhibit 6-ND-induced smooth muscle contractions, we have hypothesized that negative chronotropism induced by α1-AR antagonists reflects 6-ND blockade. This study investigated whether selective α1-AR antagonists affect 6-ND-induced positive chronotropism in isolated rat atria. Alfuzosin at 10 nM did not affect the atrial rate, but at 100 nM, it significantly reduced the atrial rate. This effect was not observed in L-NAME (100 mM)-treated preparations or in atria from rats chronically treated with L-NAME. Alfuzosin (100 nM) significantly reduced the 6-ND-induced positive chronotropism without affecting the chronotropic responses to noradrenaline, adrenaline, or dopamine. Similar results were obtained with doxazosin (1-10 nM), tamsulosin (10-100 nM), and prazosin (1-10 nM). Isoprenaline induced concentration-dependent increases in atrial rate, which were not significantly affected by any of these α1-AR antagonists. The results demonstrated that α1-AR antagonists reduced atrial basal rate only at concentrations affecting the positive chronotropic effect of 6-ND, and this reduction was not observed when NO synthesis was blocked, indicating that the negative chronotropic effect may involve 6-ND receptor blockade.

  • Open Access

    Assessing the reaction to and efficacy of the Screener drug discovery and development board game as a pedagogical tool in postgraduate courses

    by F. Noël, G. Xexéo, M.A. Martins, E.J.R. Silva, A.S. Pupo, P.J.C. Magalhães, R.C.P. Lima-Júnior, K.K.L. Gadelha, K. Lima-Silva, J.M. Raimundo, et al.

    Screener, a board game supplemented with online resources, was introduced and distributed by the Brazilian Society of Pharmacology and Experimental Therapeutics to postgraduate programs as an instructional tool for the process of drug discovery and development (DDD). In this study, we provided a comprehensive analysis of five critical aspects for evaluating the quality of educational games, namely: 1) description of the intervention; 2) underlying pedagogical theory; 3) identification of local educational gaps; 4) impact on diverse stakeholders; and 5) elucidation of iterative quality enhancement processes. We also present qualitative and quantitative assessments of the effectiveness of this game in 11 postgraduate courses. We employed the MEEGA+ online survey, comprising thirty-three close-ended unipolar items with 5-point Likert-type response scales, to assess student perceptions of the quality and utility of Screener. Based on 115 responses, the results indicated a highly positive outlook among students. In addition, we performed a preliminary evaluation of learning outcomes in two courses involving 28 students. Pre- and post-quizzes were applied, each consisting of 20 True/False questions directly aligned with the game's content. The analysis revealed significant improvement in students' performance following engagement with the game, with scores rising from 8.4 to 13.3 (Pt-test) and 9.7 to 12.7 (Pt-test). These findings underscore the utility of Screener as an enjoyable and effective tool for facilitating a positive learning experience in the DDD process. Notably, the game can also reduce the educational disparities across different regions of our continental country.


  • Open Access

    The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors

    by Richard G. W. Proudman, Andre S. Pupo, Jillian G. Baker

    α1‐adrenoceptor antagonists are widely used for hypertension (eg, doxazosin) and benign prostatic hypertrophy (BPH, eg, tamsulosin). Some antidepressants and antipsychotics have been reported to have α1 affinity. This study examined 101 clinical drugs and laboratory compounds to build a comprehensive understanding of α1‐adrenoceptor subtype affinity and selectivity. [3H]prazosin whole‐cell binding was conducted in CHO cells stably expressing either the full‐length human α1A, α1B, or α1D‐adrenoceptor. As expected, doxazosin was a high‐affinity nonselective α1‐antagonist although other compounds (eg, cyclazosin, 3‐MPPI, and ARC239) had higher affinities. Several highly α1A‐selective antagonists were confirmed (SNAP5089 had over 1700‐fold α1A selectivity). Despite all compounds demonstrating α1 affinity, only BMY7378 had α1D selectivity and no α1B‐selective compounds were identified. Phenoxybenzamine (used in pheochromocytoma) and dibenamine had two‐component‐binding inhibition curves at all three receptors. Incubation with sodium thiosulfate abolished the high‐affinity component suggesting this part is receptor mediated. Drugs used for hypertension and BPH had very similar α1A/α1B/α1D‐adrenoceptor pharmacological profiles. Selective serotonin reuptake inhibitors (antidepressants) had poor α1‐adrenoceptor affinity. Several tricyclic antidepressants (eg, amitriptyline) and antipsychotics (eg, chlorpromazine and risperidone) had high α1‐adrenoceptor affinities, similar to, or higher than, α blockers prescribed for hypertension and BPH, whereas others had poor α1 affinity (eg, protriptyline, sulpiride, amisulpiride, and olanzapine). The addition of α blockers for the management of hypertension or BPH in people already taking tricyclic antidepressants and certain antipsychotics may not be beneficial. Awareness of the α‐blocking potential of different antipsychotics may affect the choice of drug for those with delirium where additional hypotension (eg, in sepsis) may be detrimental.


  • Open Access

    Revisiting the Pharmacodynamic Uroselectivity of α1-Adrenergic Receptor Antagonists

    by Bruna Maria Castro Salomão Quaresma, Amanda Reis Pimenta, Anne Caroline Santos da Silva, André Sampaio Pupo, Luiz Antonio S. Romeiro, Claudia Lucia Martins Silva, François Noël

    α1-adrenoceptor (AR) antagonists are widely used for the relief of urinary retention secondary to benign prostatic hyperplasia (BPH). While the five FDA-approved α1-AR antagonists (terazosin, doxazosin, alfuzosin, tamsulosin and silodosin) share similar efficacy, they differ in tolerability with reports of ejaculatory dysfunction. The aim of the present work was to revisit their α1-AR subtype selectivity as well as of LDT5, a compound previously described as a multi-target antagonist of α1A-/α1D-AR and 5-HT1A receptors, and to estimate their affinity for D2, D3 and 5-HT1A receptors, putatively involved in ejaculatory dysfunction. Competition binding assays were performed with native (D2, 5-HT1A) or transfected (human α1A-, α1B-, α1Dt-AR and D3) receptors for determination of drug9s affinities. Tamsulosin and silodosin have the highest affinities for α1A-AR, but only silodosin is clearly a selective α1A-AR antagonist with Ki ratios of 25.3 and 50.2, for the α1D-AR and α1B-AR, respectively. Tamsulosin, silodosin and LDT5, but not terazosin, doxazosin and alfuzosin, have high affinity for the 5-HT1AR (Ki around 5-10 nM), behaving as antagonists. We conclude that the uroselectivity of tamsulosin is not explained by its too low selectivity for the α1A- vs. α1B-AR and that its affinity for D2 and D3 receptors is probably too low for explaining the ejaculatory dysfunction reported for this drug. Present data also support the design of »better-than-LDT5» new multi-target lead compounds with pharmacokinetics selectivity based on poor brain penetration and that could prevent hyperplastic cell proliferation and BPH progression. SIGNIFICANCE STATEMENT Present work revisits the uroselectivity of the five FDA-approved α1 adrenoceptor antagonists for the treatment of benign prostatic hyperplasia (BPH). Contrarily to what has been claimed by some, our results indicate that the uroselectivity of tamsulosin is probably not fully explained by its too weak selectivity for the α1A vs. α1B adrenoceptors. We also show that tamsulosin affinity for D3 and 5-HT1A receptors is probably too low for explaining the ejaculatory dysfunction reported for this drug. Based on our lead compound LDT5, present data support the search for a multi-target antagonist of α1A-α1D and 5-HT1A receptors with poor brain penetration as an alternative for BPH treatment.


  • Open Access

    Updates in the function and regulation of α1‐adrenoceptors

    by Juliana Akinaga, J. Adolfo García‐Sáinz, André S. Pupo

    α1‐Adrenoceptors are seven transmembrane domain GPCRs involved in numerous physiological functions controlled by the endogenous catecholamines, noradrenaline and adrenaline, and targeted by drugs useful in therapeutics. Three separate genes, whose products are named α1A‐, α1B‐, and α1D‐ adrenoceptors, encode these receptors. Although the existence of multiple α1‐adrenoceptors has been acknowledged for almost 25 years, the specific functions regulated by each subtype are still largely unknown. Despite the limited comprehension, the identification of a single class of subtype‐selective ligands for the α1A‐ adrenoceptors, the so‐called α‐blockers for prostate dysfunction, has led to major improvement in therapeutics, demonstrating the need for continued efforts in the field. This review article surveys the tissue distribution of the three α1‐adrenoceptor subtypes in the cardiovascular system, genitourinary system, and CNS, highlighting the functions already identified as mediated by the predominant activation of specific subtypes. In addition, this review covers the recent advances in the understanding of the molecular mechanisms involved in the regulation of each of the α1‐adrenoceptor subtypes by phosphorylation and interaction with proteins involved in their desensitization and internalization.Linked Articles: This article is part of a themed section on Adrenoceptors—New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc


  • Open Access

    Complex interactions of sibutramine with α 1D ‐adrenoceptors

    by Andre Sampaio Pupo, Fernanda Diehl Nojimoto, Juliana Akinaga, Vanessa Lima

    This study investigates the interactions of sibutramine, a hypophagic drug non‐selective inhibitor of norepinephrine (NE) and 5‐HT uptake, with the α 1 ‐ARs subtypes of the rat vas deferens (α 1A ), spleen (α 1B ) and aorta (α 1D ) and with human α 1 ‐ARs subtypes expressed in HEK 293 cells. Sibutramine potentiated the contractions induced by NE in the vas deferens, consistent with an indirect sympathomimetic action. In the rat spleen, sibutramine (up to 100 μM) was unable to affect the contractions induced by NE, suggesting it is inactive at α 1B ‐ARs. In rat aorta sibutramine 3 to 100 μM competitively antagonized the contractions induced by NE (Schild slope = 0.95 ± 0.05; pA 2 = 5.5 ± 0.1) indicating it interacts with α 1D ‐ARs. Sibutramine inhibited the specific binding of [ 3 H]‐prazosin to membranes from HEK cells expressing α 1A ‐ARs and α 1B ‐ARs with very low affinities (pK i ≈ 3.5). Low concentrations of sibutramine (30 nM to 1 μM) partially inhibited (≈50%) the specific binding of [ 3 H]‐prazosin to membranes from HEK cells expressing α 1D ‐ARs. In dissociation experiments, a low concentration of sibutramine (0.3 μM) increased by 5‐fold the dissociation of [ 3 H]‐prazosin from membranes of HEK cells expressing α 1D ‐ARs whereas sibutramine 10 μM delayed it by 3‐fold. Although presenting complex behavior in radioligand binding assays, sibutramine interacts selectively with native and recombinant α 1D ‐ARs.